期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

GP和NP方案治疗复发转移乳腺癌44例效果及不良反应观察 被引量：5

暂未订购
导出
摘要 目的:观察GP方案和NP方案治疗对蒽环类和(或)紫杉类耐药的复发转移性晚期乳腺癌的疗效及不良反应。方法:按照随机对照原则,将44例乳腺癌患者分为GP组和NP组。GP组给予吉西他滨(GEM)1000mg/m2,静滴,d1,8;顺铂(DDP)25mg/m2,静滴,d3～5。NP方案给予长春瑞滨(NVB)25mg/m2,静滴,d1,8;DDP用法同前。以世界卫生组织(Wold Health Organization,WHO)肿瘤疗效标准和毒性反应为评定标准。2种方案均21d为1个周期,2个周期后评定疗效。结果:GP组中CR3例,PR11例,RR63.6%。NP组中CR3例,PR9例,RR54.5%。结论:GP方案或NP方案治疗对蒽环类和(或)紫杉类耐药的复发转移性晚期乳腺癌的疗效较好,不良反应可以耐受。
作者 蒋兆荣 吴宜嘉 蔡进
机构地区 江苏省泰兴市人民医院肿瘤内科
出处 《南通大学学报（医学版）》 2011年第1期68-69,共2页 Journal of Nantong University(Medical sciences)
关键词 晚期乳腺癌 吉西他滨 长春瑞滨 顺铂 化学治疗
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献6

二级参考文献41

  • 1谢国明,李海霞.吉西他滨联合顺铂对蒽环类及紫杉类耐药的晚期乳腺癌的治疗[J].中国肿瘤,2007,16(5):382-383. 被引量：13
  • 2徐兵河.蒽环类耐药性乳腺癌的治疗策略[J].中华肿瘤杂志,2007,29(4):241-244. 被引量：85
  • 3Spielmann M, Llombart Cussac A, Kalla S, et al. Single-agent gemcitabine is active in previously treated metastatic breast cancer[J].Oncology ,2001,60(4): 303-307.
  • 4Rha SY ,Jeung H,Kim Y,et al,Efficacy of gemcitabine as a salvage treatment in breast cancer patients refractory to anthracycline and paclintaxel based regimen[J]. Proc ASCO,2002,21:A2038.
  • 5Blackstein M, Vogel CL, Ambinder R, et al. Gemcitabine as first-line therapy in patients with metastatic breast cancer: a Phase Ⅱ trial[J]. Oncology,2002,52(1) : 2-8.
  • 6Perez Manga G, Lluch A, Alba A, et al. Gemcitabine in combination with doxorubicin in advanced breast cancer: final results of a Phase Ⅱ pharmacokinetic trial[J]. J Clin Oncol, 2000,18(13):2545-2552.
  • 7Campone M, Viens P, Dieras V, et al. Gemzar (G) and epirubicin (E) in patients (PTS) with metastatic breast cancer:results of a Phase Ⅱ trial[J].Proc ASCO,2001,20:A1940.
  • 8Gomez H, Kahatt C, Falcon S, et al. A phase Ⅱ study of neoadjuvant gemcitabine plus doxorubicin in Stage Ⅲ b breast cancer: a preliminary report[J]. Semin Oncol ,2001,28(3 Suppl 10):57-61.
  • 9Sanchez Rovira P, Gonzalez E, Medina MB, et al. Results from a Phase Ⅱ study of gemcitabine in combination with paclitaxel in metastatic breast cancer (MBC) [J]. Breast Cancer Res Treat, 1999,57(1):87.
  • 10Murad AM, Guimaraes RC, Aragao BC, et al. Gemcitabine and paditaxel as salvage therapy in metastatic breast cancer[J]. Oncology,2001,15(2 Suppl 3) :25-27.

共引文献109

同被引文献50

  • 1王涛,江泽飞,宋三泰,申戈,张少华,张志强,曾敏.希罗达治疗乳腺癌所致手足综合征的发生规律及临床处理[J].癌症进展,2004,2(4):258-260. 被引量：67
  • 2Shamscddinc A,Khalifch M,Chchal A. A clinical phase Ⅱ study of cisplatinum and vinorelbinc(PVn) in advanced breast carcinoma (ABC)[J].AM J Clin Oncol,2005,28(4):393-398.
  • 3Clinical trials of vnorelbine in breast cancer-its scientific usefulness and development history until regulatory approval[J].Gam To Kaqaku,2006,33 (4):541-547.
  • 4周际昌.实用肿瘤内科学[M].北京:人民卫生出版社,2005:601～610.
  • 5Matsumoto J,Minami T,Takami M,et al. A case resect- able hepatic metastases of breast cancer {ollowing intrahe- patic arterial chemotherapy[J]. Gan To Kagaku Ryoho, 1996,23(11) :1542-1545.
  • 6Fumoleau P,Delgado FM,Delozier T, et al. Phase Ⅱ trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy[J]. J Clin Oncol, 1993, 11 (7) : 1245-1252.
  • 7Terenziani M, Demicheli R, Brambilla C, et al. Vinorel bine: an active, non cross resistant drug in advanced breast cancer. Results from a phase Ⅱ study[J]. Breast Cancer Res Treat,J996,39(3):285-291.
  • 8Morishita M, Leonard RC. Capecitabine and docetaxel combination for the treatment of breast cancer [J]. Womens Health (Lond Engl),2008,4:11 -22.
  • 9Jemal A, Bray F, Center MM, et al. Global cancer statistics[ J]. CA Cancer J C1in,2011,61 ( 2 ) :69 - 90.
  • 10Nagourney RA, Link JS, Blitzer J, et al. Gemcitabine plus cisplatin repeating double therapy in previously treated relapsed breast cancer patients [ J ]. J Clin 0ncol,2000, 18 ( 1 ) : 2245 - 2249.

引证文献5

二级引证文献24

南通大学学报（医学版）
2011年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部